Please wait a minute...
European Journal of Gynaecological Oncology  2018, Vol. 39 Issue (5): 769-772    DOI: 10.12892/ejgo4240.2018
Original Research Previous articles | Next articles
Expression of plasma miR-106a in epithelial ovarian cancer and its diagnostic and prognostic significance
Jing Zhao1, *(), Xue Dong2, Qing-cui Liu3, Qun Lu4
1 Department of Reproduction, The Children & Women's Healthcare of LaiWu City, LaiWu, Shandong Province, China
2 Department of Obstetrics and Gynecology, The Children & Women's Healthcare of LaiWu City, LaiWu, Shandong Province, China
3 Department of Obstetrics, The Children & Women's Healthcare of LaiWu City, LaiWu, Shandong Province, China
4 Department of reproduction, Peking University People's Hospital, Beijing, China
Download:  PDF
Export:  BibTeX | EndNote (RIS)      
Abstract  
Aims: Circulating microRNAs (miRs) have been investigated as promising novel biomarkers for cancer diagnosis and prognosis. The aim of this study was to evaluate the expression level of plasma miR-106a in patients with epithelial ovarian cancer (EOC) and investigate its clinical significance. Materials and Methods: By using qRT-PCR, the authors compared plasma miR-106a expression in 95 EOC patients and 100 healthy volunteers. The association between plasma miR-106a level and clinicopathological factors was also analyzed. Furthermore, they explored whether plasma miR-106a could serve as a useful biomarker for EOC diagnosis and prognosis. Results: Plasma miR-106a was up-regulated in EOC patients compared with healthy controls (p < 0.01). High plasma miR-106a levels were significantly associated with advanced FIGO stage, high CA125 expression, poor cancer differentiation, and shorter overall survival. ROC curve analysis showed that plasma miR-106a was capable of distinguishing EOC from control subjects. Multivariate Cox regression analysis confirmed high plasma miR-106a expression as an independent unfavorable prognostic factor for EOC. Conclusions: Plasma miR-106a was upregulated in EOC patients and might serve as a novel non-invasive diagnostic and prognostic biomarker.
Key words:  miR-106a      biomarker      epithelial ovarian cancer      diagnosis      prognosis     
Published:  10 October 2018     
*Corresponding Author(s):  JING ZHAO     E-mail:  zhing128@mail.com

Cite this article: 

Jing Zhao, Xue Dong, Qing-cui Liu, Qun Lu. Expression of plasma miR-106a in epithelial ovarian cancer and its diagnostic and prognostic significance. European Journal of Gynaecological Oncology, 2018, 39(5): 769-772.

URL: 

https://ejgo.imrpress.com/EN/10.12892/ejgo4240.2018     OR     https://ejgo.imrpress.com/EN/Y2018/V39/I5/769

[1] Chados Nikolaos, Gregoriou Odysseas, Salakos Nicolaos, Kondis Agatha, Deligeoroglou Efthymios. The prognostic significance and immuno-expression of survivin, mutant p53 and bcl-2 in 92 cases of epithelial ovarian cancer[J]. European Journal of Gynaecological Oncology, 2020, 41(4): 517-522.
[2] Sun Yi Choe, Jung-Woo Park. Prognostic significance of the number of metastatic lymph nodes in early cervical cancer: a retrospective study[J]. European Journal of Gynaecological Oncology, 2020, 41(4): 536-540.
[3] Panteleimon Mnimatidis, Abraham Pouliakis, George Valasoulis, George Michail, Aris Spathis, Christine Cottaridi, Niki Margari, Maria Kyrgiou, Maria Nasioutziki, Alexandros Daponte, Konstantinos Dinas, Evangelos Paraskevaidis, Ioannis Panayiotides, Dimitrios-Dionysios Koutsouris. Multicentric assessment of cervical HPV infection co-factors in a large cohort of Greek women[J]. European Journal of Gynaecological Oncology, 2020, 41(4): 545-555.
[4] Gen-Hai Zhu, Kang Wang, Lan Hong, Xin-Hui Fu, Fu-Jin Liu, Hai-Yan Huang. Safety and efficacy of fertility-sparing surgery for an orthotopic xenograft model of epithelial ovarian cancer in nude mice[J]. European Journal of Gynaecological Oncology, 2020, 41(4): 609-616.
[5] B.-H. Zhang, L. Li, J. Ji, J. Guo, X.-L. Zhou, H. Xu, F. Cao, X.-H. Tong. Prognostic value of Foxp3+ regulatory T cells in endometrial cancer: a meta-analysis[J]. European Journal of Gynaecological Oncology, 2020, 41(3): 339-342.
[6] S.R Oh, J.-W. Park. Is the Risk of Malignancy Index a predictive tool for preoperative differentiation between borderline ovarian tumor and ovarian cancer?[J]. European Journal of Gynaecological Oncology, 2020, 41(3): 368-374.
[7] Emine Karabuk, Burak Karadag, Ceyda Karadag, M. Faruk Kose, M. Murat Naki, E. Nilufer Guler. The outcomes of fertility sparing surgery in epithelial ovarian cancer[J]. European Journal of Gynaecological Oncology, 2020, 41(3): 391-395.
[8] Chenchen Zhu, Hanyuan Liu, Zhen Shen, Yanhu Xie, Tianjiao Zhang, Björn Nashan, Dabao Wu, Ying Zhou. Treatment and survival outcomes from epithelial ovarian cancer in women aged 65 years or older[J]. European Journal of Gynaecological Oncology, 2020, 41(3): 415-421.
[9] Jingyuan Wang, Xiaoping Li, Danhua Shen, Xiao Wang, Zhiqi Wang, Jianliu Wang. Clear-cell carcinoma of the endometrium:type I or type II endometrial carcinoma?[J]. European Journal of Gynaecological Oncology, 2020, 41(3): 449-454.
[10] T. Sakamoto, M. Miyamoto, T. Kono, H. Tsuada, H. Matsuura, T. Aoyama, M. Takano, K. Furuya. Endometrial dedifferentiated carcinoma: a case report. Pathological review at a single institution and systematic review of published literature[J]. European Journal of Gynaecological Oncology, 2020, 41(2): 163-166.
[11] M. Pakiž, A. Dovnik, B. Crnobrnja, P. Zola. Increased incidence of advanced stage endometrial cancer: a retrospective analysis of different clinical approaches and tumour biology[J]. European Journal of Gynaecological Oncology, 2020, 41(2): 246-251.
[12] Can Fang, Yan Zhao, Kezhen Li, Danhui Weng, Peng Wu, Gang Chen, Ding Ma, Juncheng Wei. Diabetes mellitus and epithelial ovarian cancer in Chinese women: a retrospective cohort study[J]. European Journal of Gynaecological Oncology, 2020, 41(2): 260-264.
[13] K. Sonoda, M. Nogami, K. Kodama, Y. Oda, K. Kato. Re-evaluation of preoperative endometrial smears for the cytodiagnosis of uterine leiomyosarcoma[J]. European Journal of Gynaecological Oncology, 2020, 41(2): 167-170.
[14] X.Q. Wang, S.Q. Ma, J.Y. Guo, F. Zhao, X.H. Liang. Characteristics and prognostic factors among premenopausal versus postmenopausal patients with advanced endometrial cancer: a SEER-based analysis[J]. European Journal of Gynaecological Oncology, 2020, 41(1): 1-6.
[15] X.Z. Cheng, Z. Zhou, M.Y. Yang, Y.L. Cai, F. Deng, X.X. Chen. Prognostic factors for types I and II epithelial ovarian cancer in the elderly[J]. European Journal of Gynaecological Oncology, 2020, 41(1): 7-15.
No Suggested Reading articles found!